Patients Treated with Vyepti Report Satisfaction with Impact on Symptoms of Chronic Migraine

The majority of people with chronic migraine who were treated with Vyepti (eptinezumab-jjmr; Lundbeck, Copenhagen, Denmark) reported that they were satisfied with the efficacy of the medication, and they had higher satisfaction with elements of daily living and overall well-being following treatment. These findings were presented at the 2023 Scottsdale Headache Symposium.

The REVIEW study was an observational, real-world study conducted at 4 in the United States, which included 94 adult participants with a diagnosis of chronic migraine who were treated with at least 2 consecutive Vyepti infusions. These participants had tried prior therapies, which failed, with 89% having previous exposure to a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb). Analysis was conducted from data obtained from a patient survey and a semi-structured interview with a health care provider. 

Participants indicated that they were satisfied with the efficacy of Vyepti treatment, with the majority reporting that the medication:

• Made migraine symptoms less severe (80% agreed)
• Made migraine symptoms less frequent (76% agreed)
• Reduced how long migraine symptoms lasted (67% agreed)
• Reduced symptoms other than head pain (61% agreed)
• Provided faster relief of symptoms (57% agreed)

Participants also indicated that since starting Vyepti, they had higher or much higher:

• Ability to plan their lives (70% reported)
• Participation with social/family life (69% reported)
• Productivity at usual daily responsibilities (68% reported)
• Ability to return to responsibilities faster (62% reported)

In terms of wellbeing, since the start of treatment with Vyepti:

• 57% of participants reported greater confidence in their overall wellbeing.
• 38% reported greater energy levels.
• 29% reported greater sleep quality.
• 30% reported that their anxiety and stress levels were lower or much lower.

In addition to these data describing improved participant satisfaction, the REVIEW study also demonstrated that treatment with Vyepti was effective in increasing the number of “good days” per month and reducing the use of acute migraine medication, while also decreasing symptoms of cognitive impairment.

“Cognitive impairment from migraine actually impacts activities of daily living, work, productivity, engagement with family, and engagement with social life,” said Dr. Marija S. Geertsen, Vice President of US Medical Affairs at Lundbeck. “It will be important to further study the correlation between improvement in cognitive impairment, and improvement in patient functioning in different domains of their daily life.”